LACTONATAL+DHA SOFTGEL CAPSULE/TABLET

Indications

• Isolated carboxylase defects
• Defects of biotin metabolism
• Prevention of deficiency in complete biliary obstruction

Dosage

Children: Neonate: Initially 10 mg once daily, adjusted according to response; maintenance 5–20 mg daily. Child: Initially 10 mg once daily, adjusted according to response; maintenance 5–20 mg daily, higher doses may be required.

Adults: For adults, the dosing may vary based on the condition being treated. General guidance is to refer to the BNF for specific dosing recommendations.

Mechanism of action

Biotin acts as a coenzyme for carboxylase enzymes, facilitating critical metabolic processes including gluconeogenesis, fatty acid synthesis, and amino acid catabolism.

Pharmacodynamics

Biotin is essential for the carboxylation of substrates in metabolic pathways, influencing energy metabolism and the synthesis of important biomolecules. It supports normal growth and development.

Pharmacokinetics

Biotin is absorbed in the intestine and is widely distributed in body tissues. It is not stored in large amounts, with excess being excreted in urine. The half-life and specific pharmacokinetic parameters can vary based on individual metabolism and dietary intake.

Adverse effects

• Rough skin
• Dry hair
• Enlarged liver
• Increases in erythrocyte sedimentation rate
• Increased serum calcium
• Increased serum alkaline phosphatase concentration

Precautions

• Excessive doses may be teratogenic
• High levels of vitamin A may cause birth defects

Pregnancy

No information available.

Breast-feeding

No information available.

Formulations

• Tablet
• Oral suspension
• Oral solution
• Solution for injection

Indications

• Gastroesophageal reflux disease (GERD)
• Peptic ulcers
• Dyspepsia
• Acid-base balance disorders

Dosage

Children: Refer to specific acid formulations and guidelines for dosing. General dosing depends on the acid and its clinical use.

Adults: Refer to specific acid formulations and guidelines for dosing. General dosing depends on the acid and its clinical use.

Mechanism of action

Acids exert their effects primarily by dissociating into protons and anions in solution, thereby lowering the pH of the surrounding environment. This proton donation can influence various physiological processes, including enzyme activity, ion transport, and cellular signaling pathways. For example, hydrochloric acid in the stomach aids in digestion and the absorption of certain nutrients.

Pharmacodynamics

The pharmacodynamic effects of acids are largely dependent on their concentration and the specific type of acid involved. Weak acids may dissociate partially, leading to a less pronounced effect, while strong acids fully dissociate, leading to significant changes in pH and potential tissue irritation. Acids can also interact with various receptors and enzymes, influencing metabolic pathways and physiological responses.

Pharmacokinetics

The pharmacokinetics of acids vary widely depending on their chemical structure. Strong acids, such as hydrochloric acid, do not significantly enter systemic circulation due to their rapid dissociation in aqueous environments. Weak acids may be absorbed through the gastrointestinal tract, where their absorption is influenced by pH, solubility, and the presence of food. Metabolism and excretion pathways also vary, with some acids being metabolized to bicarbonate or other metabolites before excretion, primarily via the kidneys.

Adverse effects

• Gastrointestinal irritation
• Nausea
• Vomiting
• Abdominal pain
• Diarrhea
• Electrolyte imbalance

Precautions

• Use with caution in patients with renal impairment
• Monitor for signs of gastrointestinal bleeding
• Consider potential interactions with other medications that may affect gastrointestinal motility or pH levels

Pregnancy

The safety of various acids during pregnancy may vary; consult specific guidelines for each acid. Generally, use should be limited to essential cases.

Breast-feeding

Caution is advised when using acids during breastfeeding; consult specific guidelines for each acid.

Storage

Store in a cool, dry place away from direct sunlight. Keep tightly closed and out of reach of children.

Indications

• Support for cognitive function
• Cardiovascular health
• Anti-inflammatory effects
• Eye health
• Neuroprotection

Dosage

Children: Refer to specific product guidelines or clinical recommendations for dosage.

Adults: Refer to specific product guidelines or clinical recommendations for dosage.

Mechanism of action

DHA is incorporated into cell membranes, particularly in the brain and retina, where it contributes to membrane fluidity and function. It serves as a precursor for the synthesis of neuroprotective and anti-inflammatory mediators, including resolvins and protectins, which help to modulate inflammatory responses and promote neuronal health.

Pharmacodynamics

DHA influences various physiological processes, including lipid metabolism, inflammation, and neuronal signaling. It has been shown to enhance synaptic plasticity and cognitive functions, and it may exert cardioprotective effects by improving endothelial function and reducing triglyceride levels. DHA also plays a role in the modulation of gene expression related to inflammation and lipid metabolism.

Pharmacokinetics

DHA is absorbed from the gastrointestinal tract and distributed throughout the body, particularly to the brain and retina. Its bioavailability can be influenced by dietary factors and the presence of other fatty acids. Metabolism occurs primarily through beta-oxidation and incorporation into phospholipids, with elimination taking place via the bile and urine. The half-life of DHA varies, but its effects can be prolonged due to incorporation into tissue.

Adverse effects

• Nausea
• Diarrhea
• Gastrointestinal discomfort
• Increased bleeding tendency
• Allergic reactions

Interactions

• Anticoagulants (e.g., warfarin) - may increase the risk of bleeding
• Antiplatelet drugs - may enhance the effects of these medications

Precautions

• Use caution in patients with a known allergy to fish or shellfish
• Monitor bleeding in patients taking anticoagulants or antiplatelet medications
• Consult healthcare provider before use in patients with liver disease

Pregnancy

DHA is generally considered safe during pregnancy, but high doses should be avoided unless prescribed by a healthcare provider.

Breast-feeding

DHA is beneficial during breastfeeding, as it can support infant brain development, but consult a healthcare provider for dosage.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Formulations

• Softgel capsules
• Liquid fish oil
• Fortified foods and beverages

Indications

• Hyperlipidemia
• Cardiovascular disease prevention
• Rheumatoid arthritis
• Inflammatory bowel disease
• Major depressive disorder

Dosage

Children: Refer to BNF for Children for specific dosing guidelines.

Adults: Refer to BNF for specific dosing guidelines, generally available in the form of supplements or prescription formulations.

Mechanism of action

Eicosapentaenoic acid works by influencing the production of eicosanoids, which are signaling molecules derived from fatty acids. It competes with arachidonic acid in the enzymatic pathways, leading to the production of less inflammatory eicosanoids. This shift in eicosanoid production is believed to contribute to reduced inflammation and improved cardiovascular outcomes.

Pharmacodynamics

The pharmacodynamic effects of EPA include the modulation of lipid levels, reduction of triglycerides, and anti-inflammatory effects. It has been shown to decrease platelet aggregation and may improve endothelial function, thus contributing to cardiovascular protection.

Pharmacokinetics

Eicosapentaenoic acid is readily absorbed from the gastrointestinal tract following oral administration. It undergoes metabolic processes in the liver and is incorporated into cell membranes, affecting cell signaling and inflammatory responses. The half-life of EPA is variable, influenced by dosage and individual metabolism, and it is primarily excreted in the urine and feces.

Adverse effects

• Nausea
• Diarrhea
• Abdominal pain
• Flatulence
• Rash

Precautions

• Use with caution in patients with known hypersensitivity to fish or shellfish.
• Monitor patients on anticoagulant therapy due to potential for increased bleeding risk.

Pregnancy

There are no adequate and well-controlled studies in pregnant women. Eicosapentaenoic acid should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Eicosapentaenoic acid is excreted in breast milk. Caution should be exercised when administering to nursing mothers.

Storage

Store in a cool, dry place, away from direct sunlight. Keep out of reach of children.

Formulations

• Capsules
• Liquid formulations

Indications

• Nutritional support
• Management of dyslipidemia
• Support for cardiovascular health
• Anti-inflammatory therapies

Dosage

Children: Refer to the BNF for Children for specific dosing recommendations based on age and condition.

Adults: Dosage varies widely depending on the specific type of fatty acid and the condition being treated. Refer to specific guidelines for dietary or therapeutic doses.

Mechanism of action

Fatty acids exert their effects through several mechanisms, including serving as energy sources, components of cell membrane phospholipids, and precursors for signaling molecules such as eicosanoids. They can modulate gene expression and influence metabolic pathways by activating nuclear receptors, such as peroxisome proliferator-activated receptors (PPARs).

Pharmacodynamics

Fatty acids influence lipid metabolism, inflammation, and insulin sensitivity. They can alter membrane fluidity and receptor function, impacting cellular signaling. Saturated fatty acids may promote inflammatory processes, while unsaturated fatty acids, particularly omega-3 and omega-6 fatty acids, can exert anti-inflammatory effects and promote cardiovascular health.

Pharmacokinetics

Fatty acids are absorbed in the intestine via passive diffusion and are transported in the blood bound to albumin or as part of lipoproteins. They are metabolized in the liver, where they can undergo beta-oxidation to generate energy or be converted into ketone bodies. The half-life varies depending on the type of fatty acid and its incorporation into various tissues.

Pregnancy

Consult with a healthcare provider before use, as the effects of fatty acids during pregnancy can vary.

Breast-feeding

Consult with a healthcare provider before use, as some fatty acids may be excreted in breast milk.

Storage

Store in a cool, dry place away from direct sunlight.

Indications

• Folate deficiency
• Megaloblastic anemia
• Prevention of neural tube defects in pregnancy
• Supplementation in patients on certain medications (e.g., methotrexate)

Dosage

Children: Refer to the BNF for Children for appropriate pa

Adults: Refer to specific guidelines or the BNF for appropriate adult dosing based on the indication.

Mechanism of action

Folate functions as a coenzyme in the conversion of homocysteine to methionine, a process that is vital for DNA synthesis and repair. It is involved in the one-carbon metabolism pathway, where it acts as a carrier of one-carbon units necessary for the synthesis of purines and thymidylate, thus supporting the production of nucleotides and DNA. This mechanism is particularly important in rapidly dividing cells.

Pharmacodynamics

Folate is critical for the formation of red blood cells and the proper functioning of the nervous system. It aids in the production of nucleic acids, which are essential for cell proliferation. Folate deficiency can lead to impaired DNA synthesis, resulting in megaloblastic anemia characterized by the presence of large, immature red blood cells in the bloodstream. Adequate folate levels are also associated with reduced risk of neural tube defects in developing fetuses.

Pharmacokinetics

Folate is absorbed in the proximal part of the small intestine, primarily in the jejunum, and is transported in the bloodstream bound to plasma proteins. It undergoes hepatic metabolism and is stored mainly in the liver. The elimination half-life varies, but dietary folate can be retained in the body for several weeks. Excess folate is excreted through the urine. The bioavailability of folate from food sources is lower compared to synthetic folic acid found in supplements.

Interactions

• folates+fluorouracil: Severe (increases risk of toxicity)
• folates+antiepileptics: Moderate (decreases concentration)
• folates+fosphenytoin: Moderate (decreases concentration)
• folates+phenobarbital: Moderate (decreases concentration)
• folates+phenytoin: Moderate (decreases concentration)
• folates+primidone: Moderate (decreases concentration)
• sulfasalazine+folates: Unknown (decreases absorption)

Pregnancy

Folate is essential for fetal development and is often recommended to prevent neural tube defects.

Breast-feeding

Folate is generally safe during breastfeeding, as it is important for both maternal and infant health.

Storage

Store in a cool, dry place, away from direct sunlight.

Formulations

• Tablets
• Injection

Indications

• Iodine deficiency
• Goiter
• Hypothyroidism
• Thyroiditis
• Fibrocystic breast disease

Dosage

Children: Refer to the BNF for Children for appropriate dosing guidelines based on age and weight.

Adults: Refer to the BNF for appropriate dosing guidelines based on condition and clinical judgment.

Mechanism of action

Molecular iodine inhibits the induction and promotion of carcinogenesis in mammary tissues and has shown beneficial effects in fibrocystic breast disease. It temporarily decreases thyroid hormone production through the acute Wolff-Chaikoff effect, followed by a return to normal hormone synthesis due to down regulation of the sodium-iodide symport. This mechanism can lead to a transient hypothyroid state in some individuals with underlying thyroid conditions.

Pharmacodynamics

Iodine is vital for the synthesis of thyroid hormones thyroxine (T4) and triiodothyronine (T3). It affects the metabolism of amine-derived hormones and plays a role in amino acid metabolism. The acute excess of iodide can lead to decreased circulating levels of T4 and T3 in susceptible individuals, while most people can escape this effect and maintain normal thyroid function.

Pharmacokinetics

Iodine is absorbed primarily in the gastrointestinal tract and is distributed throughout the body, particularly in the thyroid gland, where it is concentrated for hormone synthesis. The kidney plays a significant role in the excretion of excess iodine. The half-life of iodine in the body varies and can be influenced by dietary intake and underlying health conditions.

Adverse effects

• Hypothyroidism
• Hyperthyroidism
• Iodine allergy
• Gastrointestinal disturbances

Interactions

• Thyroid hormones
• Antithyroid drugs
• Lithium
• Diuretics

Precautions

• Use with caution in patients with thyroid dysfunction
• Monitor thyroid function periodically during treatment
• Pregnant or breastfeeding women should consult a healthcare provider before use

Pregnancy

Iodine is essential for fetal thyroid hormone synthesis, but excessive iodine intake should be avoided.

Breast-feeding

Iodine is excreted in breast milk; consult a healthcare provider regarding supplementation.

Storage

Store in a cool, dry place away from light.

Formulations

• Iodine solution
• Iodine tincture
• Potassium iodide tablets

Indications

• Vitamin B3 deficiency
• Hyperlipidemia
• Dyslipidemia

Mechanism of action

Niacin decreases lipids and apolipoprotein B (apo B)-containing lipoproteins by modulating triglyceride synthesis in the liver and inhibiting lipolysis in adipose tissue. It inhibits hepatocyte diacylglycerol acyltransferase-2, preventing the final step of triglyceride synthesis, leading to reduced VLDL production. Additionally, niacin inhibits HDL catabolism receptors, increasing HDL levels and half-life. Acute effects include inhibition of nonesterified fatty acid release from adipocytes and stimulation of prostaglandin release from skin Langerhans cells, although these acute effects diminish over time.

Pharmacodynamics

Niacin is used therapeutically to treat vitamin deficiencies and to manage conditions like hyperlipidemia and dyslipidemia. It effectively reduces levels of VLDL and LDL while increasing HDL levels. Niacin has a wide therapeutic window, with typical oral doses ranging from 500 mg to 2000 mg. Caution is advised in patients with diabetes, renal failure, uncontrolled hypothyroidism, and in elderly patients, particularly when combined with simvastatin or lovastatin, due to an increased risk of myopathy and rhabdomyolysis.

Pharmacokinetics

Niacin is absorbed from the gastrointestinal tract and undergoes hepatic metabolism. It is excreted primarily in the urine. The pharmacokinetics can be affected by factors such as age, renal function, and concomitant medications. Peak plasma concentrations are typically reached within 30 minutes to 2 hours after oral administration, depending on the formulation used.

Contra-indications

• Hypersensitivity to niacin or any of its components
• Active liver disease
• Peptic ulcer disease

Adverse effects

• Flushing
• Itching
• Nausea
• Vomiting
• Diarrhea
• Abdominal pain
• Hepatotoxicity
• Hyperglycemia
• Gout exacerbation

Interactions

• Increased risk of myopathy and rhabdomyolysis with statins such as simvastatin or lovastatin
• May enhance the effects of antihypertensive medications
• Potential interaction with anticoagulants

Precautions

• Caution in patients with diabetes due to potential for hyperglycemia
• Monitor liver function tests periodically during prolonged therapy
• Use with caution in patients with renal impairment
• Elderly patients may be more susceptible to adverse effects

Pregnancy

Niacin should only be used during pregnancy if clearly needed and the benefits outweigh the risks. Consult with a healthcare provider for individual assessment.

Breast-feeding

Niacin is excreted in breast milk. Caution is advised when administering to nursing mothers, and a decision should be made whether to discontinue breastfeeding or the drug.

Storage

Store at room temperature, away from moisture and heat. Keep out of reach of children.

Formulations

• Immediate-release tablets
• Extended-release tablets
• Sustained-release tablets

Indications

• Pantothenic acid deficiency
• Supportive treatment for adrenal insufficiency
• Supplementation in conditions of increased metabolic demand
• Potential use in improving energy metabolism

Dosage

Children: Refer to established guidelines for pediatric doses, which may vary based on age and dietary needs, generally aligning with recommended daily allowances.

Adults: Refer to established guidelines for supplementation and dietary intake, typically ranging from 5 to 10 mg daily for adults, depending on specific conditions and dietary intake.

Mechanism of action

Pantothenic acid is a precursor to coenzyme A, a cofactor necessary for the metabolism of fatty acids and carbohydrates. Coenzyme A is involved in the synthesis and oxidation of fatty acids, the metabolism of pyruvate in the citric acid cycle, and the synthesis of cholesterol and steroid hormones. By facilitating these metabolic pathways, pantothenic acid contributes to energy production and the biosynthesis of essential biomolecules.

Pharmacodynamics

Pantothenic acid is integral in the synthesis of coenzyme A, which plays a crucial role in the metabolism of carbohydrates, proteins, and fats. It aids in the conversion of food into energy and is also involved in the synthesis of neurotransmitters and hormones. Adequate levels of pantothenic acid are necessary for maintaining normal physiological functions and overall health.

Pharmacokinetics

Pantothenic acid is absorbed in the gastrointestinal tract and is widely distributed throughout body tissues. It is primarily excreted in the urine, with minimal storage in the body. The half-life of pantothenic acid in the body is relatively short, necessitating regular dietary intake to maintain adequate levels.

Adverse effects

• Diarrhea
• Nausea
• Abdominal cramping
• Fatigue
• Irritability

Precautions

• Use with caution in patients with known hypersensitivity to pantothenic acid or any component of the formulation.
• Monitor patients for gastrointestinal side effects.

Pregnancy

Pantothenic acid is generally considered safe during pregnancy, but it is important to consult a healthcare provider for individual assessment.

Breast-feeding

Pantothenic acid is secreted in breast milk; however, it is considered safe for breastfeeding mothers. Consultation with a healthcare provider is recommended.

Storage

Store in a cool, dry place, away from direct sunlight. Keep out of reach of children.

Formulations

• Capsules
• Tablets
• Powder for oral solution
• Injectable form

Indications

• Thiamine deficiency
• Beriberi
• Wernicke-Korsakoff syndrome
• Metabolic disorders
• Supportive treatment in chronic alcoholism

Dosage

Children: Refer to established guidelines or specific product information for appropriate paediatric dosing, as it may vary based on the condition being treated.

Adults: Refer to established guidelines or specific product information for appropriate adult dosing, as it may vary based on the condition being treated.

Mechanism of action

Thiamine is a cofactor for several enzymes, including pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase, which are critical in the metabolic pathways of glucose and energy production. By facilitating these enzymatic reactions, thiamine helps in the conversion of glucose into energy, thus supporting cellular metabolism.

Pharmacodynamics

Thiamine exerts its effects primarily on the nervous system and cardiovascular system. It aids in the synthesis of acetylcholine, a neurotransmitter that is vital for nerve function. Thiamine deficiency can lead to neurological symptoms such as confusion, memory loss, and in severe cases, can cause coma or death. Its role in carbohydrate metabolism also means that adequate levels are important for maintaining energy levels and overall metabolic health.

Pharmacokinetics

Thiamine is absorbed in the intestine and is actively transported into cells. It is distributed throughout the body, with high concentrations found in the liver, heart, and brain. It is excreted in urine, and due to its water-soluble nature, the body does not store large amounts of thiamine. Therefore, regular dietary intake is essential to maintain adequate levels.

Adverse effects

• Allergic reactions
• Anaphylaxis
• Nausea
• Vomiting
• Irritation at the injection site

Interactions

• May interact with certain diuretics
• Potential interaction with antineoplastic agents

Precautions

• Caution in patients with known hypersensitivity to thiamine
• Use with caution in patients with renal impairment

Pregnancy

Vitamin B1 is generally considered safe during pregnancy and is important for fetal development.

Breast-feeding

Vitamin B1 is excreted in breast milk; supplementation may be necessary in breastfeeding mothers at risk of deficiency.

Storage

Store in a cool, dry place away from light. Keep out of reach of children.

Formulations

• Oral tablets
• Injectable solution
• Extended-release formulations

Mechanism of action

Biotin is necessary for the proper functioning of enzymes that transport carboxyl units and fix carbon dioxide, and is required for various metabolic functions, including gluconeogenesis, lipogenesis, fatty acid biosynthesis, propionate metabolism, and catabolism of branched-chain amino acids. In human tissues biotin is a cofactor for the enzymatic carboxylation of four substrates: pyruvate, acetyl coenzyme A (CoA), propionyl CoA, and beta-methylcrotonyl CoA. As such, it plays an important role in both carbohydrate and fat metabolism. Carbon dioxide fixation occurs in a two-step reaction, the first involving binding of carbon dioxide to the biotin moiety of the holoenzyme, and the second involving transfer of the biotin-bound carbon dioxide to an appropriate acceptor. Biotin functions in carbon dioxide fixation reactions in intermediate metabolism, transferring the carboxyl group to acceptor molecules. It acts similarly in decarboxylation reactions. Biotin is essential in human metabolism for its part in the previously described enzymatic steps, in catalyzing deamination of amino acids, and in oleic acid synthesis. Biotin is a cofactor for the enzymatic carboxylation of pyruvate, acetyl coenzyme A (CoA), propionyl CoA, and beta-methylcrotonyl CoA, and, therefore, plays an important role in carbohydrate and fat metabolism. Protein folding in the endoplasmic reticulum (ER) depends on Ca2+; uptake of Ca2+ into the ER is mediated by sarco/endoplasmic reticulum Ca2+-ATPase 3 (SERCA3). The 5'-flanking region of the SERCA3 gene (ATP2A3) contains numerous binding sites for the transcription factors Sp1 and Sp3. Biotin affects the nuclear abundance of Sp1 and Sp3, which may act as transcriptional activators or repressors. Here we determined whether biotin affects the expression of the SERCA3 gene and, thus, protein folding in human lymphoid cells. Jurkat cells were cultured in media containing 0.025 nmol/L biotin (denoted "deficient") or 10 nmol/L biotin ("supplemented"). The transcriptional activity of the full-length human SERCA3 promoter was 50% lower in biotin-supplemented cells compared to biotin-deficient cells. Biotin-dependent repressors bind to elements located 731 to 1312 bp upstream from the transcription start site in the SERCA3 gene. The following suggest that low expression of SERCA3 in biotin-supplemented cells impaired folding of secretory proteins in the ER, triggering unfolded protein response: (i) sequestration of Ca2+ in the ER decreased by 14 to 24% in response to biotin supplementation; (ii) secretion of interleukin-2 into the extracellular space decreased by 75% in response to biotin supplementation; (iii) the nuclear abundance of stress-induced transcription factors increased in response to biotin supplementation; and (iv) the abundance of stress-related proteins such ubiquitin activating enzyme 1, growth arrest and DNA damage 153 gene, X-box binding protein 1 and phosphorylated eukaryotic translation initiation factor 2alpha increased in response to biotin supplementation. Collectively, this study suggests that supplements containing pharmacological doses of biotin may cause cell stress by impairing protein folding in the ER. Evidence is emerging that biotin participates in processes other than classical carboxylation reactions. Specifically, novel roles for biotin in cell signaling, gene expression, and chromatin structure have been identified in recent years. Human cells accumulate biotin by using both the sodium-dependent multivitamin transporter and monocarboxylate transporter 1. These transporters and other biotin-binding proteins partition biotin to compartments involved in biotin signaling: cytoplasm, mitochondria, and nuclei. The activity of cell signals such as biotinyl-AMP, Sp1 and Sp3, nuclear factor (NF)-kappaB, and receptor tyrosine kinases depends on biotin supply. Consistent with a role for biotin and its catabolites in modulating these cell signals, greater than 2000 biotin-dependent genes have

Pharmacodynamics

Biotin is a water-soluble B-complex vitamin which is composed of an ureido ring fused with a tetrahydrothiophene ring, which attaches a valeric acid substituent at one of its carbon atoms. Biotin is used in cell growth, the production of fatty acids, metabolism of fats, and amino acids. It plays a role in the Kreb cycle, which is the process in which energy is released from food. Biotin not only assists in various metabolic chemical conversions, but also helps with the transfer of carbon dioxide. Biotin is also helpful in maintaining a steady blood sugar level. Biotin is often recommended for strengthening hair and nails. Consequenty, it is found in many cosmetic and health products for the hair and skin. Biotin deficiency is a rare nutritional disorder caused by a deficiency of biotin. Initial symptoms of biotin deficiency include: Dry skin, Seborrheic dermatitis, Fungal infections, rashes including erythematous periorofacial macular rash, fine and brittle hair, and hair loss or total alopecia. If left untreated, neurological symptoms can develop, including mild depression, which may progress to profound lassitude and, eventually, to somnolence; changes in mental status, generalized muscular pains (myalgias), hyperesthesias and paresthesias. The treatment for biotin deficiency is to simply start taking some biotin supplements. A lack of biotin in infants will lead to a condition called seborrheic dermatitis or "cradle cap". Biotin deficiencies are extremely rare in adults but if it does occur, it will lead to anemia, depression, hair loss, high blood sugar levels, muscle pain, nausea, loss of appetite and inflamed mucous membranes.

Mechanism of action

Molecular iodine is known to inhibit the induction and promotion of N-methyl-n-nitrosourea-induced mammary carcinogenesis, to regress 7,12-dimethylbenz(a)anthracene-induced breast tumors in rats.It has also been shown to have beneficial effects in fibrocystic human breast disease. An acute iodide excess (above the preexisting dietary intake) transiently decreases the production of thyroid hormones in the thyroid gland; this is referred to as the acute Wolff-Chaikoff effect. In normal people, this is followed by a return to normal levels of hormone synthesis, referred to as escape from the acute Wolff-Chaikoff effect, without a significant change in circulating hormone levels. Escape is thought to be the result of down regulation of the sodium-iodide symport (NIS), the iodide transporter in the thyroid gland, resulting in a decrease in the intrathyroidal iodine and the resumption of normal hormone synthesis. An acute or chronic excess of iodide can also decrease circulating T4 and T3 levels and induce a hypothyroid state in some people who have underlying thyroid disorders. These effects are the result of a failure to escape from the acute Wolff-Chaikoff effect. Most people who experience iodine-induced hypothyroidism recover when the excess iodine intake is discontinued.

Mechanism of action

Niacin performs a number of functions in the body and so has many mechanisms, not all of which have been fully described. Niacin can decrease lipids and apolipoprotein B (apo B)-containing lipoproteins by modulating triglyceride synthesis in the liver, which degrades apo B, or by modulating lipolysis in adipose tissue. Niacin inhibits hepatocyte diacylglycerol acyltransferase-2. This action prevents the final step of triglyceride synthesis in hepatocytes, limiting available triglycerides for very low density lipoproteins (VLDL). This activity also leads to intracellular degradation of apo B and decreased production of low density lipoproteins, the catabolic product of VLDL. Niacin also inhibits a high density lipoprotein (HDL) catabolism receptor, which increases the levels and half life of HDL. Prolonged niacin treatment elicits beneficial effects on the plasma lipid and lipoprotein profile that is associated with a protective CVD risk profile. Acute niacin treatment inhibits nonesterified fatty acid release from adipocytes and stimulates prostaglandin release from skin Langerhans cells, but the acute effects diminish upon prolonged treatment, while the beneficial effects remain. To gain insight in the prolonged effects of niacin on lipid metabolism in adipocytes, we used a mouse model with a human-like lipoprotein metabolism and drug response [female APOE*3-Leiden.CETP (apoE3 Leiden cholesteryl ester transfer protein) mice] treated with and without niacin for 15 weeks. The gene expression profile of gonadal white adipose tissue (gWAT) from niacin-treated mice showed an upregulation of the "biosynthesis of unsaturated fatty acids" pathway, which was corroborated by quantitative PCR and analysis of the FA ratios in gWAT. Also, adipocytes from niacin-treated mice secreted more of the PUFA DHA ex vivo. This resulted in an increased DHA/arachidonic acid (AA) ratio in the adipocyte FA secretion profile and in plasma of niacin-treated mice. Interestingly, the DHA metabolite 19,20-dihydroxy docosapentaenoic acid (19,20-diHDPA) was increased in plasma of niacin-treated mice. Both an increased DHA/AA ratio and increased 19,20-diHDPA are indicative for an anti-inflammatory profile and may indirectly contribute to the atheroprotective lipid and lipoprotein profile associated with prolonged niacin treatment. /The study objective was/ to determine the effects of niacin on adiponectin and markers of adipose tissue inflammation in a mouse model of obesity. Male C57BL/6 mice were placed on a control or high-fat diet (HFD) and were maintained on such diets for the duration of the study. After 6 weeks on the control or high fat diets, vehicle or niacin treatments were initiated and maintained for 5 weeks. Identical studies were conducted concurrently in HCA2 (-/-) (niacin receptor(-/-)) mice. Niacin increased serum concentrations of the anti-inflammatory adipokine, adiponectin by 21% in HFD-fed wild-type mice, but had no effect on lean wild-type or lean or HFD-fed HCA2 (-/-) mice. Niacin increased adiponectin gene and protein expression in the HFD-fed wild-type mice only. The increases in adiponectin serum concentrations, gene and protein expression occurred independently of changes in expression of PPARgamma C/EBPalpha or SREBP-1c (key transcription factors known to positively regulate adiponectin gene transcription) in the adipose tissue. Further, niacin had no effect on adipose tissue expression of ERp44, Ero1-Lalpha, or DsbA-L (key ER chaperones involved in adiponectin production and secretion). However, niacin treatment attenuated HFD-induced increases in adipose tissue gene expression of MCP-1 and IL-1beta in the wild-type HFD-fed mice. Niacin also reduced the expression of the pro-inflammatory M1 macrophage marker CD11c in HFD-fed wild-type mice. Niacin treatment attenuates obesity-induced adipose tissue inflammation through increased adiponectin and anti-inflammatory cytokine expression and reduced pro-inflammatory cytokine expressio

Pharmacodynamics

Niacin is a B vitamin used to treat vitamin deficiencies as well as hyperlipidemia, dyslipidemia, hypertriglyceridemia, and to reduce the risk of myocardial infarctions. Niacin acts to decrease levels of very low density lipoproteins and low density lipoproteins, while increasing levels of high density lipoproteins. Niacin has a wide therapeutic window with usual oral doses between 500mg and 2000mg. Patients with diabetes, renal failure, uncontrolled hypothyroidism, and elderly patients taking niacin with simvastatin or lovastatin are at increased risk of myopathy and rhabdomyolysis.